| Name | Title | Contact Details |
|---|
Formativ Health is a management services organization that is redefining Practice Management and end-to-end Revenue Cycle through the integration of technology-enabled Patient Access, Revenue Cycle Management, Practice Operations and Advisory Services. At Formativ Health our approach is simple: We seek to understand your strategy and business goals so that we can define solutions tailored to your needs and designed to maximize performance. As the health care industry continues to transform, we partner with providers to successfully improve their financial health, adapt to changing risk-based payment models, increase physician productivity and satisfaction, and enhance the patient experience. Our technology-enabled services are designed to provide flexibility across the full continuum of Practice Management and Revenue Cycle
Cary HealthCare L L C is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
As the nation’s leading community oncology alliance, RainTree Oncology Services assists our member practices in achieving better and more cost effective treatment of oncology patients while creating new streams of revenue for community oncology practices through. Creating a unique aggregated data compilation and analytic platform allowing RainTree members to develop and evaluate care pathways to improve patient care and outcomes while reducing costs to the health care system; and Developing commercial relationships accelerating innovative oncology treatments and payer arrangements while optimizing oncology patient care and advancing the science of oncology.
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.